Teva confirms appointment of Erez Vigodman as president and CEO
Somewhat sooner than expected, Israel’s Teva Pharmaceutical Industries (NYSE: TEVA), the world’s largest generics drugmaker, has confirmed recent reports, saying that Erez Vigodman has been appointed president and chief executive, effective February 11.
Mr Vigodman (pictured) will succeed acting president and CEO Eyal Desheh, who was temporarily named to the post following the ousting of former CEO Jeremy Levin last fall (The Pharma Letter October 30, 2013), and he will return to his previous position as group executive vice president and chief financial officer of the company. Mr Desheh had been viewed by some as a permanent candidate for the post.
Teva chairman Phillip Frost commented: “As a member of the Teva Board since 2009, Erez has a deep understanding of the company and the industry in which it operates, putting him in a strong position to hit the ground running and deliver value for shareholders.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze